Antibacterial compounds

1. A compound of formula (1):

A-L 1 -Y-L 2 -R—B  (1)

wherein

A is a cyclic group having the following formulae (I):

wherein

G 1 is CH or N;

G 2 is CR 1 or N;

R 1 is hydrogen atom, halogen atom, cyano or (C 1-3 )alkoxy group;

L 1 is σ bond, or (C 1-3 )alkylenyl group, optionally substituted with hydroxy group;

Y is a ring selected from the group consisting of piperidinyl, piperazinyl, pyrrolidinyl, 1-3 cyclobutyl, 1-3 cyclopentyl, 1-2 cyclopropyl, azetidinyl, azabicyclo-octyl, morpholinyl and cyclohexyl ring, said ring being optionally substituted by one or more substituent selected from the group consisting of hydroxy group, (C 1-3 )alkylenyl-OH group, (C 1-3 )alkylenyl-O—(C 1-3 )alkyl group, (C 1-3 )alkylenyl-CONR′R″ group, and CONR′R″ group, wherein R′ and R″ are hydrogen atom or (C 1-3 )alkyl;

L 2 is σ bond, —(C 1-3 )alkylenyl- group, NR′″ group, NR′″—(C 1-3 )alkylenyl group, (C 1-3 )alkylenyl-NR′″ group, NR′″—(C 1-3 )alkylenyl-NR′″ group, or (C 1-3 )alkylenyl-NR′″ —(C 1-3 )alkylenyl group, said group being optionally substituted with a hydroxy group, wherein R′″ is hydrogen, (C 1-3 )alkyl, (C 1-3 )alkylenyl-OH, (C 1-3 )alkylenyl-O—(C 1-3 )alkyl, or (C 1-3 )alkylenyl-CONR′R″, wherein R′ and R″ are hydrogen atom or (C 1-3 )alkyl;

R is σ bond or heterocyclic ring, aliphatic or aromatic, having 5 members containing one or more nitrogen atoms, optionally substituted with CH 2 OH, CH 2 CN, CN or CONR′R″, wherein R′ and R″ are hydrogen atom or (C 1-3 )alkyl; and

B is cyclic group having the following formulae (V):

wherein

G 6 is CH or N;

G 7 is CH or N; and

R 2 is hydrogen atom or halogen atom,

with the proviso that when Y is piperidinyl ring or piperazinyl ring, if A is represented by formula (I) and B is represented by formula (V), then G 2 is only N,

or an addition salt with a pharmaceutically acceptable organic or inorganic acid or base, an enantiomer, an N-oxide, or a quaternary ammonium salt of said compound of formula (1).

2. The compound according to claim 1 , wherein R 1 is a halogen atom, a cyano group, or an alkoxy group having from 1 to 2 carbon atoms.

3. The compound according to claim 2 , wherein R 1 is selected from the group consisting of a fluorine atom, a chlorine atom, a cyano group and a methoxy group.

4. The compound according to claim 1 , wherein L 1 is a σ bond or a methylene group (—CH 2 ).

5. The compound according to claim 1 , wherein L 2 is a σ bond, a (C 1-3 )alkylenyl group, NR′″ group, —NR′″—(C 1-3 )alkylenyl group, (C 1-3 )alkylenyl-NR′″— group, —NR′″—(C 1-3 )alkylenyl-NR′″— group, or (C 1-3 )alkylenyl-NR′″—(C 1-3 )alkylenyl group, said group being optionally substituted with one or more hydroxy group.

6. The compound according to claim 5 , wherein L 2 is a σ bond, a (C 1-2 )alkylenyl group, NR′″ group, —NR′″—(C 1-2 )alkylenyl group, (C 1-2 )alkylenyl-NR″′— group, —NR′″—(C 1-2 )alkylenyl-NR′″— group, or (C 1-2 )alkylenyl-NR′″—(C 1-2 )alkylenyl group, said group being optionally substituted with one hydroxy group.

7. The compound according to claim 1 , wherein R is a σ bond or an aromatic heterocyclic ring having 5 members containing one or more nitrogen atoms, optionally substituted with CH 2 CN or CN.

8. The compound according to claim 7 , wherein R is a σ bond, a 1H-imidazol-4-yl group, or a 1H-pyrrol-2-yl group, optionally substituted with CH 2 CN or CN.

9. The compound according to claim 1 , wherein A is a cyclic group having one of the following formulae:

10. The compound according to claim 1 , wherein Y is a ring having one of the following formulae:

11. The compound according to claim 1 , wherein B is a cyclic group having one of the following formulae:

12. A pharmaceutical composition, comprising at least one compound, salt thereof with a pharmaceutically acceptable organic or inorganic acid or with a pharmaceutically acceptable organic or inorganic base, enantiomer, quaternary ammonium salt, or N-oxide according to claim 1 , and

at least one inert pharmaceutically acceptable excipient.

13. A method for treating a bacterial infection, comprising administering an effective amount of a compound, salt with a pharmaceutically acceptable organic or inorganic acid or with a pharmaceutically acceptable organic or inorganic base, enantiomer, quaternary ammonium salt, or N-oxide according to claim 1 to a patient in need thereof.

14. The method according to claim 13 , wherein said bacterial infection is selected from the group consisting of a skin infection, a mucosal infection, a gynecological infection, a respiratory tract infection (RTI), a CNS infections, a gastro-intestinal infection, a bone infection, a cardiovascular infection, a sexually transmitted infection, and a urinary tract infection.

15. The compound according to claim 1 , wherein Y is a ring having one of the following formulae:

16. The method of according to claim 13 , wherein said bacterial infection is an E. coli infection or an S. aureus infection.

17. The method of according to claim 13 , wherein said bacterial infection is an E. coli infection.

18. The method of according to claim 13 , wherein said bacterial infection is an S. aureus infection.